Core Insights - CervoMed is advancing its drug candidate neflamapimod for treating dementia with Lewy bodies (DLB), a condition with no approved treatments in the US or EU [1][6] - The company plans to initiate a Phase 3 trial in DLB patients, specifically targeting those without Alzheimer's disease co-pathology, in the second half of 2026 [6] Group 1: Clinical Trial Results - In the Phase 2b RewinD-LB trial, neflamapimod showed a statistically significant and clinically meaningful slowing of clinical progression in DLB patients without Alzheimer's disease co-pathology [2] - Secondary analyses will present new outcomes based on pre-specified plasma pTau181 levels, supporting the planned Phase 3 trial's patient selection criteria [2] Group 2: Upcoming Presentations - CervoMed will present findings at the AD/PD 2026 conference in Copenhagen, including an oral presentation on neflamapimod's treatment effects in DLB patients [5] - A scientific symposium sponsored by CervoMed will discuss advances in DLB research and new drug development strategies, featuring presentations from leading researchers [4] Group 3: Drug Development Strategy - Neflamapimod targets critical disease processes in neuroinflammation and neurodegeneration, aiming to inhibit a key enzyme involved in these processes [6] - The company is focusing on understanding the dose-response relationship of neflamapimod through new pharmacokinetic and pharmacodynamic analyses from the RewinD-LB trial [4]